AM-Pharma Announces Appointment of Russell Greig as Chairman
2012-01-04
AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of recombinant human Alkaline Phosphatase (AP) for treatment of Acute Kidney Injury and Inflammatory bowel diseases, today announced the appointment of Dr Russell Greig as Chairman of the Supervisory Board.
Accera, Inc. Elects Industry Veteran Holger Kunze as CEO and as a Member of the Company’s Board of Directors
2012-01-03
- Accera, Inc., announced today that Holger Kunze has been appointed to the position of Chief Executive Officer and as a member of the company's Board of Directors (BoD). Concurrently, Sven Thormahlen, Ph.D., has also been appointed as a member of Accera's BoD.
TOPCRYO™, up in the air with LSG Sky Chefs Germany
2011-11-22
- CRYOLOG with TOPCRYOTM, a microbiological Time Temperature Integrator, is involved in a process of quality insurance and traceability with the German company, LSG Sky Chefs Germany, a worldwide recognized provider of best-in-class products in airline catering. This tool enables LSG Sky Chefs Germany to safeguard cold chain monitoring in real time and in this way, to preserve foodstuffs during long-haul flights between Europe, America and Asia.
Sino-UK companies announce TB vaccine partnership deal
2011-10-17
- ImmunoBiology Ltd, is pleased to announce the signing of an initial cooperation agreement with LIBP, a subsidiary company under Sinopharm's biological products division - CNBG (China National Biotech Group).
Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
2011-10-12
- "Following our successful fundraising in June, we are delighted to have now treated the first patients in the AEGIS Phase 3 programme and we remain on course to have top line results from these studies in late 2012. Effective treatment of IDA represents a very attractive commercial opportunity and the start of recruitment is an important milestone for Shield Therapeutics as we continue the rapid development of ST10 to address this significant unmet need for the many patients with IDA." said Carl Sterritt, Chief Executive Officer and Co-Founder of Shield Therapeutics.
Phagenesis Closes €7 Million Series B Financing Round
2011-10-04
- Phagenesis Ltd, the global leader in the treatment of dysphagia (inability to swallow safely) today announced that it has closed a €7 million Series B funding round designed to accelerate the company's development plans.
MSI Methylation Sciences Raises EUR13.5 Million From Inventages Venture Capital via Series A Institutional
2011-09-29
- This new investment will help fund the clinical development of MSI's formulations of s-adenosyl methionine (SAMe) to clinical proof of concept. MSI's leads are the first generation of MSI SAMe formulations with superior properties and are ready for clinical trials.
- "We are delighted to have successfully completed this fundraising and to have secured sufficient funds to take our lead molecule into formal clinical development," said Barry Guld, Chief Executive Officer and President ofMSI. "We look forward to working with the Inventages team."
Steaz Pledges $15,000 to Non-Profit Whole Planet Foundation to Help Fight World Poverty
2011-09-28
- Steaz is the maker of USDA Certified Organic and Fair Trade Certified Steaz® Organic Iced Teaz, Steaz® Sparkling Green Teas, Steaz® ZERO Calorie Sparkling Green Teas, and Steaz® Energy, all recipients of BevNet.com's "Best of" awards. Steaz is recognized as a leading innovator in the ready to drink tea category as well as its worldwide social responsibility initiatives.
- "Learn more about the Whole Planet Foundation"
Life and disability claims: strategies for a technology-enabled world
2011-09-26
- A new report Life and disability claims: strategies for a technology-enabled world produced jointly by Karin Lloyd and SelectX takes a fresh, strategic look at the claims process in today's fast-changing world - in which technology is transforming life for consumers and the businesses that serve them.
AM-Pharma Raises €29.2m in Series D Financing
2011-09-13
- This fundraising will enable AM-Pharma to advance its human recombinant form of human AP from preclinical stages through to the end of phase II as a treatment for Acute Kidney Injury (AKI).
- The series D round was led by Ysios Capital Partners, co-led by Kurma Life Science Partners and supported by a consortium including the venture arms of two global Healthcare companies, Abbott and Shire, the European venture funds, BB Biotech Ventures and Idinvest Partners as well as existing investors, Forbion Capital Partners and Inventages Venture Capital.
Neuroptix Co-Founder Goldstein awarded NASA funding
2011-09-09
Palu Saxon's Pea, Apple and Mint Soups!
2011-09-01
- The managers of Tanfield Foods "Look what we found!" are not just proud to have found small British regional farmer Paul Saxon, but also to have created a recipe combining his beautiful produce with two ingredients which partner them so well!
Accera: novel therapies and video
2011-08-05
-
Accera is uniquely targeting metabolic defects in neurodegenerative disorders for the treatment of Alzheimer's disease. Axona® is a prescription medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease. The human brain relies almost exclusively on glucose as a source of energy. Research shows that, in Alzheimer's disease patients, there is a dramatic drop in the brain's ability to metabolize glucose.
-
Axona is a medical food regulated by the FDA that addresses energy deficiencies in the brain by providing an alternative source of energy. This is very well described in the video link.
Vital Foods partners with Nestlé Health Science
2011-07-18
- "We are delighted to partner with Nestlé Health Science," said Dr. Gursh Bindra, CEO of Vital Foods. "Together, we are now well positioned to provide nutrition solutions for digestive medical conditions; for example constipation, which is commonly reported by patients with irritable bowel syndrome."
- Founded in 1991 with strong agricultural science credentials, Vital Foods has captured a strong market position in the New Zealand market with its kiwifruit-based digestive health products.
Opsona Therapeutics announces initiation of a Phase 1 clinical trial with its lead drug
2011-07-05
- Commenting on this announcement; Bernd R. Seizinger, M.D., Ph.D., Executive Chairman of Opsona Therapeutics said," OPN-305 is a first-in-class antibody against Toll-like- Receptor 2, one of the most promising novel drug targets in the innate immune system. TLR-2 has been linked to an increasing number of major human diseases, including autoimmune diseases, renal ischemia, myocardial infarction, stroke and cancer. This phase 1 study will provide the basis to explore the broad medical and commercial viability and opportunity of OPN- 305 in a variety of indications with unmet medical needs."
Moobella Names Medfield Resident Steve Beck its First Chief
2011-06-11
- Former Senior VP With Leading Global Foodservice Equipment Manufacturer To Spearhead MooBella's Commercial/OperationalStrategy.
Shield Therapeutics Raises 8.2 million
2011-06-01
- The investment by Inventages follows the recent completion of a final private investor led fundraising and was made at a post-money valuation of €35m (CHF43m/US$51m). The investment is scheduled in two equal tranches over the next two years. Prior to the investment by Inventages, Shield Therapeutics successfully completed three private investment rounds, raising a total of approximately €6 million (CHF7.5m/US$9.0m). The new investment will help fund the Phase III pivotal development programme and subsequent filing of a marketing authorisation.
Pasteur test passed successfully!
2011-01-21
- XOLUTION is happy to announce, that the system also successfully passed the Pasteur Test, allowing brands to use the can with drinks that need to be pasteurized at up to 72° Celsius.
University of Nottingham and ImmunoBiology Ltd (“ImmBio”) initiate Clostridium difficile Vaccine Programme,
2010-08-10
- ImmunoBiology ("ImmBio") is developing a novel approach to vaccines using Heat shock protein Complexes. A prophylactic vaccine could be used in various situations, such as ahead of hospitalisation, for those facing long term care and for groups most threatened by infection, such as chemotherapy patients.
CMPT announces the injection of a €1.5million convertible loan from Inventages
2010-07-29
- CMPT's lead compound has Over the Counter (OTC) potential as a treatment for the common cold; clinical trials presently under way.
- CMPT has been supported solely by investments from Geneva based Inventages Venture Capital and New Zealand based BioPacificVentures since 2005.
